These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion. Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879 [TBL] [Abstract][Full Text] [Related]
6. Delayed Pressure Urticaria: Clinical and Diagnostic Features and Response to Omalizumab. Veleiro-Pérez B; Alba-Muñoz J; Pérez-Quintero O; Rodríguez RL; Calvín-Lamas M; Parra-Arrondo A Int Arch Allergy Immunol; 2022; 183(10):1089-1094. PubMed ID: 35609554 [TBL] [Abstract][Full Text] [Related]
7. Recalcitrant chronic urticaria treated with dupilumab: Report of two instances refractory to H1-antihistamines, omalizumab and cyclosporine and brief literature review. Errichetti E; Stinco G Dermatol Ther; 2021 Mar; 34(2):e14821. PubMed ID: 33506984 [No Abstract] [Full Text] [Related]
8. Clinical Characteristics, Investigations and Treatment in Children with Chronic Urticaria: An Observational Study. Buono EV; Giannì G; Scavone S; Caffarelli C Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792886 [No Abstract] [Full Text] [Related]
10. Treatment with omalizumab or cyclosporine for resistant chronic spontaneous urticaria. Koski R; Kennedy KK Ann Allergy Asthma Immunol; 2017 Nov; 119(5):397-401. PubMed ID: 29150066 [No Abstract] [Full Text] [Related]
11. Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria? Thiede RM; Fazel M; MacDonald KM; Abraham I Expert Opin Pharmacother; 2022 Oct; 23(14):1563-1567. PubMed ID: 36173375 [No Abstract] [Full Text] [Related]
12. Cyclosporine and omalizumab together: A new option for chronic refractory urticaria. Sánchez J; Alvarez L; Cardona R J Allergy Clin Immunol Pract; 2020 Jun; 8(6):2101-2103. PubMed ID: 32112923 [No Abstract] [Full Text] [Related]
13. H1-Antihistamines May No Longer Be Necessary for Patients With Refractory Chronic Spontaneous Urticaria After Initiation of Omalizumab. Ensina LF; Arruda LK; Campos RA; Criado RF; Rodrigues Valle S; Melo JM; Oliveira JC; Dortas JS; Cusato-Ensina AP; Camelo-Nunes IC; Agondi RC J Investig Allergol Clin Immunol; 2020 Apr; 30(2):145-147. PubMed ID: 31762438 [No Abstract] [Full Text] [Related]
14. The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update. Maurer M; Zuberbier T; Metz M Handb Exp Pharmacol; 2022; 268():117-133. PubMed ID: 34247278 [TBL] [Abstract][Full Text] [Related]
15. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems. Sánchez J; Alvarez L; López JF Actas Dermosifiliogr; 2024 Jan; 115(1):T88-T90. PubMed ID: 37871896 [No Abstract] [Full Text] [Related]
16. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems. Sánchez J; Alvarez L; López JF Actas Dermosifiliogr; 2024 Jan; 115(1):88-90. PubMed ID: 36754254 [No Abstract] [Full Text] [Related]
17. Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review. Gimenez-Arnau AM; Salman A; Podder I Eur J Dermatol; 2024 Feb; 34(1):3-12. PubMed ID: 38557452 [TBL] [Abstract][Full Text] [Related]